NCT00948116 Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes
| NCT ID | NCT00948116 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barts & The London NHS Trust |
| Condition | Diabetes Mellitus |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2009-06-24 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2009-06-24 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients living with diabetes mellitus have double the risk of kidney failure compared to patients without diabetes following use of dye in many x-rays and procedures to diagnose and treat narrowing of the arteries (blood vessels) in the heart that can lead to angina or a heart attack. Heart disease is the commonest cause of death in patients with diabetes. People with diabetes are more likely to need these tests/treatments. By identifying those at greater risk of kidney complications we may be able to make these tests/treatments safer and offer them to more patients with diabetes.
Eligibility Criteria
Inclusion Criteria: 1. Age \> 18 years, known diabetes mellitus or BM on arrival consistent with probable diagnosis of diabetes, eGFR \<60 ml/min 2. Undergoing a PCI procedure 3. Agrees to the additional collection of blood and urine samples as outlined above 4. Agrees to access of their clinical records for the collection of relevant medical data 5. No history or signs of drug abuse 6. Able to understand and sign the written Informed Consent Form 7. Able and willing to follow the Protocol requirements Exclusion Criteria: 1. Cardiogenic shock 2. Pregnancy 3. Patient on renal replacement therapy (haemodialysis/CAPD/renal transplant) 4. Known clinically significant infection such as HIV, Hepatitis or TB 5. Any patient determined not able to make a reasoned, informed consent prior to the planned interventional procedure
Contact & Investigator
AKHIL KAPUR
PRINCIPAL INVESTIGATOR
CONSULTANT CARDIOLOGIST AND HONORARY SENIOR LECTURER, BARTS AND THE LONDON NHS TRUST
Frequently Asked Questions
Who can join the NCT00948116 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00948116 currently recruiting?
Yes, NCT00948116 is actively recruiting participants. Contact the research team at akhil.kapur@bartsandthelondon.nhs.uk for enrollment information.
Where is the NCT00948116 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT00948116 clinical trial?
NCT00948116 is sponsored by Barts & The London NHS Trust. The principal investigator is AKHIL KAPUR at CONSULTANT CARDIOLOGIST AND HONORARY SENIOR LECTURER, BARTS AND THE LONDON NHS TRUST. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.